Information Provided By:
Fly News Breaks for August 20, 2019
SRPT
Aug 20, 2019 | 08:54 EDT
RBC Capital analyst Brian Abrahams lowered his price target on Sarepta to $204 after the FDA's "unexpected" complete response letter to its golodirsen filing citing preclinical toxicity and issues observed with other antisense oligonucleotides. The analyst says the news impacts the company's risk profile across the pipeline, but he still sees "substantial" long-term value across its platfom of "game-changing, multi-billion dollar" therapies that he contends is not reflected in the stock price. Abrahams keeps his Outperform rating on Sarepta.
News For SRPT From the Last 2 Days
There are no results for your query SRPT
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.